VANTIN

Compare VANTIN  to:
Compare
Compare

Generic Name for VANTIN

Cefpodoxime proxetil 100mg, 200mg; tabs.

Legal Classification:

Rx

Pharmacological Class for VANTIN

Cephalosporin.

Manufacturer of VANTIN

Pfizer Labs

Indications for VANTIN

Susceptible mild to moderate infections including acute otitis media, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute community-acquired pneumonia, urinary tract, skin and skin structures; cervical, anorectal (females only) and urethral gonorrhea.

Adult dose for VANTIN

Take tabs with food. ≥13 yrs: Pneumonia: 200mg every 12 hours for 14 days. Bronchitis, sinusitis: 200mg every 12 hours for 10 days. Pharyngitis/tonsillitis: 100mg every 12 hours for 5–10 days. Skin and skin structures: 400mg every 12 hours for 7–14 days. UTI: 100mg every 12 hours for 7 days. Uncomplicated gonorrhea: 200mg once as a single dose. Renal failure or hemodialysis: see literature.

Children's dosing for VANTIN

Use susp. <2 months: not recommended. 2months–12yrs: Acute otitis media: 5mg/kg (max 200mg) every 12 hrs for 5 days. Pharyngitis/tonsillitis: 5mg/kg (max 100mg) every 12 hrs for 5–10 days. Sinusitis: 5mg/kg (max 200mg) every 12 hrs for 10 days.

Also:

Warnings/Precautions for VANTIN

Penicillin or other allergy. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for VANTIN

Antacids, H2 antagonists, oral anticholinergics may decrease efficacy. Potentiated by probenecid. Avoid concomitant diuretics, other nephrotoxic drugs. May cause false (+) direct Coomb's test.

Adverse Reactions for VANTIN

GI upset, abdominal pain, headache, rash, anaphylaxis.

How is VANTIN supplied?

Tabs—20, 100
Susp—50mL, 75mL, 100mL

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives
Pneumonia
Sinusitis

Related Resources

Phase 1 and 2 studies of solithromycin for the treatment of community-acquired bacterial pneumonia (CABP)

September 08, 2010

Cempra Pharmaceuticals announced that it is enrolling patients in a Phase 2 study of orally dosed solithromycin for the treatment of community-acquired bacterial pneumonia (CABP), as well as the initiation of a Phase 1 study of intravenous (IV) solithromycin.

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions